NCT02667886 2024-10-03
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
X4 Pharmaceuticals
Phase 1/2 Completed
Clinical Trials
5 trialsNCT04274738 2024-08-27
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
X4 Pharmaceuticals
Phase 1 Completed
NCT02923531 2022-12-29
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
X4 Pharmaceuticals
Phase 1/2 Terminated
NCT05103917 2021-11-02
A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC
Abbisko Therapeutics Co, Ltd
Phase 1/2 Unknown
NCT02823405 2020-07-07
X4P-001-MELA
X4 Pharmaceuticals
Phase 1 Completed